

filed, other than the manager filing this report.

[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]

NONE

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number: 3235-0006
 Estimated average burden
 hours per response: 23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8		
NAME OF ISSUER	TITLE OF CLASS	CUSIP	FIGI	VALUE	SHRS OR	SH/ PUT/	INVESTMENT	OTHER	VOTING AUTHORITY		
				(to the nearest dollar)	PRN AMT	PRN CALL	DISCRETION	MANAGER	SOLE	SHARED	NONE
2seventy bio, Inc.	Common Stock	901384107		3,689,191	1,254,827	SH	SOLE		1,254,827	0	0
Adicet Bio, Inc.	Common Stock	007002108		931,392	968,183	SH	SOLE		968,183	0	0
Adverum Biotechnologies, Inc.	Common Stock	00773U207		844,845	180,909	SH	SOLE		180,909	0	0
Alnylam Pharmaceuticals, Inc.	Common Stock	02043Q107	1,045,822,353	4,444,445		SH	SOLE		4,444,445	0	0
bluebird bio, Inc.	Common Stock	09609G209		175,140	21,000	SH	SOLE		21,000	0	0
Intellia Therapeutics, Inc.	Common Stock	45826J105		43,176,922	3,702,995	SH	SOLE		3,702,995	0	0